{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=24", "query": { "intervention": "Neoadjuvant therapy", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 2079, "total_pages": 208, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T02:24:58.359Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07414992", "title": "A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Stereotactic body radiotherapy", "type": "RADIATION" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab and Fianlimab", "type": "DRUG" }, { "name": "Radical cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-09", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07414992" }, { "nct_id": "NCT06295809", "title": "A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Carcinoma, Squamous Cell", "Skin Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Intismeran autogene", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2024-04-18", "completion_date": "2026-03-05", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 21, "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06295809" }, { "nct_id": "NCT05271604", "title": "A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma of Head and Neck", "Recurrent Squamous Cell Carcinoma of the Head and Neck", "Metastatic Cancer", "Metastatic Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Ozuriftamab Vedotin", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Evalstotug (BA3071)", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2022-12-13", "completion_date": "2025-09-22", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 7, "location_summary": "Los Angeles, California • Newark, Delaware • Chicago, Illinois + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05271604" }, { "nct_id": "NCT00072319", "title": "Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2003-08", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-03-04", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072319" }, { "nct_id": "NCT03128619", "title": "Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Multifocal Breast Carcinoma", "Postmenopausal", "Progesterone Receptor Positive", "Stage I Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Biopsy of Breast", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 10, "start_date": "2017-08-02", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2022-09-26", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128619" }, { "nct_id": "NCT01960387", "title": "Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-10", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-08-02", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01960387" }, { "nct_id": "NCT00585689", "title": "Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "ABI-007", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radical Cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-12", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2015-11-30", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585689" }, { "nct_id": "NCT03663335", "title": "Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "CFZ533 - Cohort 1/Cohort 2", "type": "BIOLOGICAL" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Corticosteroids (CS)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Induction therapy: basiliximab", "type": "DRUG" }, { "name": "Induction therapy: rabbit anti-thymocyte globulin (rATG)", "type": "DRUG" }, { "name": "Maintenance population: EC-MPS", "type": "DRUG" }, { "name": "Maintenance population: MMF", "type": "DRUG" }, { "name": "Placebo 1 mL", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 418, "start_date": "2018-11-28", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03663335" }, { "nct_id": "NCT07054190", "title": "A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2025-09-09", "completion_date": "2027-09-28", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 6, "location_summary": "Los Angeles, California • Orange, California • Germantown, Tennessee + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" }, { "city": "Flower Mound", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07054190" }, { "nct_id": "NCT01705691", "title": "Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2012-09", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2021-10-06", "last_synced_at": "2026-11-01T02:24:58.359Z", "location_count": 18, "location_summary": "Denver, Colorado • Miami Beach, Florida • Albany, Georgia + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Albany", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705691" } ] }